[HTML][HTML] Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active …

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - …, 2017 - ricerca.uniba.it
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

[PDF][PDF] Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active …

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - academia.edu
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - ONCOTARGET, 2017 - air.unimi.it
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

[PDF][PDF] Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active …

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - core.ac.uk
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

[PDF][PDF] Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active …

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - iris.unina.it
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance

M Ferro, G Lucarelli, D Bruzzese… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

[引用][C] Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active …

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - ONCOTARGET, 2017 - iris.unicz.it
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate
cancer patients meeting the inclusion criteria for active surveillance IRIS IRIS Home Sfoglia …

[PDF][PDF] Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active …

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - researchgate.net
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …

Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance

M Ferro, G Lucarelli, D Bruzzese, G Di Lorenzo… - ONCOTARGET, 2016 - fair.unifg.it
Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …